Sign In
Buy NKTR
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
Why Nektar Therapeutics Rippled Higher This Week
01:32pm, Friday, 05'th Sep 2025
Nektar Therapeutics (NKTR 7.73%) stock surged by more than 20% in the week to Friday morning. The move wasn't so much caused by anything specific to Nektar's drug development program.
What's Going On With Nektar Therapeutics Stock On Thursday?
02:52pm, Thursday, 04'th Sep 2025
Nektar Therapeutics Inc. NKTR stock traded higher on Thursday, with a session volume of 2.80 million versus the average volume of 1.96 million, according to data from Benzinga Pro.
Nektar Therapeutics to Participate in Two Investor Conferences in September
07:00pm, Wednesday, 03'rd Sep 2025
SAN FRANCISCO , Sept. 3, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C.
Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Transcript
07:48pm, Friday, 08'th Aug 2025
Nektar Therapeutics (NASDAQ:NKTR ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Howard W. Robin - CEO, President & Director Jonathan Zalevsky - Senior VP and Chief R
Why Nektar Therapeutics Stock Popped 6% on Friday
06:15pm, Friday, 08'th Aug 2025
Biotech Nektar Therapeutics (NKTR 6.02%) unveiled its latest quarterly earnings after the stock market's close on Thursday, and the investor reaction was strong the following day. Happily for Nektar,
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y
12:46pm, Friday, 08'th Aug 2025
NKTR's second-quarter top and bottom lines beat estimates. Studies on the lead candidate, rezpeg, are progressing well.
Nektar (NKTR) Q2 Revenue Falls 52%
12:51am, Friday, 08'th Aug 2025
Nektar (NKTR) Q2 Revenue Falls 52%
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
06:31pm, Thursday, 07'th Aug 2025
Nektar Therapeutics (NKTR) came out with a quarterly loss of $2.95 per share versus the Zacks Consensus Estimate of a loss of $3.13. This compares to a loss of $3.75 per share a year ago.
Nektar Therapeutics Reports Second Quarter 2025 Financial Results
04:15pm, Thursday, 07'th Aug 2025
SAN FRANCISCO , Aug. 7, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2025. Cash and investments in marketable securiti
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets
06:00pm, Thursday, 31'st Jul 2025
SAN FRANCISCO , July 31, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 7, 2025, after the close of U.S.-bas
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata
09:00am, Tuesday, 29'th Jul 2025
SAN FRANCISCO , July 29, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesl
3 Bullish Biotech Stocks With Explosive Growth Trends
11:03am, Monday, 21'st Jul 2025
Investing in biotechnology stocks is similar to the drug development process itself. That is, investors frequently experience long periods of nothing much happening, interrupted by periods of sharp mo
Why Nektar Therapeutics Stock Dived by 3% Today
07:00pm, Thursday, 03'rd Jul 2025
Nektar Therapeutics (NKTR -2.98%) saw its stock price erode on Thursday, following the company's closing of a secondary stock issue. Investors gave the company a thumbs-down on the news by selling out
SAN FRANCISCO , July 2, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherap
Nektar Therapeutics Announces Pricing of $100 Million Public Offering
07:17am, Tuesday, 01'st Jul 2025
SAN FRANCISCO , July 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the field of immunotherapy
